HC Wainwright Trims Evolus (NASDAQ:EOLS) Target Price to $34.00

Share on StockTwits

Evolus (NASDAQ:EOLS) had its target price trimmed by HC Wainwright from $37.00 to $34.00 in a report published on Thursday morning, BenzingaRatingsTable reports. The brokerage currently has a buy rating on the stock.

EOLS has been the subject of several other research reports. Svb Leerink initiated coverage on Evolus in a report on Tuesday, November 26th. They issued an outperform rating and a $25.00 price target for the company. BidaskClub raised Evolus from a strong sell rating to a sell rating in a report on Thursday. ValuEngine raised Evolus from a buy rating to a strong-buy rating in a report on Thursday, January 23rd. Mizuho assumed coverage on Evolus in a research note on Wednesday, February 5th. They issued a buy rating and a $20.00 price objective on the stock. Finally, Leerink Swann assumed coverage on Evolus in a research note on Tuesday, November 26th. They issued an outperform rating and a $25.00 price objective on the stock. Two analysts have rated the stock with a sell rating, two have assigned a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. Evolus presently has a consensus rating of Buy and an average target price of $25.18.

Evolus stock opened at $10.23 on Thursday. The business has a 50 day moving average price of $10.44 and a two-hundred day moving average price of $13.76. The company has a quick ratio of 3.28, a current ratio of 3.66 and a debt-to-equity ratio of 4.53. The stock has a market cap of $341.94 million, a price-to-earnings ratio of -3.19 and a beta of 4.30. Evolus has a 12 month low of $9.20 and a 12 month high of $29.50.

In other Evolus news, insider Rui Avelar sold 39,442 shares of the stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $10.71, for a total value of $422,423.82. Following the transaction, the insider now directly owns 70,802 shares in the company, valued at approximately $758,289.42. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 3.90% of the stock is currently owned by company insiders.

Institutional investors and hedge funds have recently made changes to their positions in the business. Ladenburg Thalmann Financial Services Inc. boosted its position in Evolus by 2,224.0% in the 2nd quarter. Ladenburg Thalmann Financial Services Inc. now owns 2,324 shares of the company’s stock valued at $34,000 after buying an additional 2,224 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of Evolus in the 4th quarter valued at $30,000. Metropolitan Life Insurance Co NY acquired a new position in shares of Evolus in the 1st quarter valued at $83,000. Royal Bank of Canada lifted its stake in shares of Evolus by 429.1% in the 2nd quarter. Royal Bank of Canada now owns 4,365 shares of the company’s stock valued at $64,000 after purchasing an additional 3,540 shares during the period. Finally, FMR LLC lifted its stake in shares of Evolus by 1,328.6% in the 4th quarter. FMR LLC now owns 5,000 shares of the company’s stock valued at $61,000 after purchasing an additional 4,650 shares during the period. Hedge funds and other institutional investors own 41.87% of the company’s stock.

About Evolus

Evolus, Inc, a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.

Featured Story: Compound Annual Growth Rate (CAGR)

Analyst Recommendations for Evolus (NASDAQ:EOLS)

Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.